Evidence map›Paper›PMID 40654581›Full record

ReviewNeuroscience applied2025

Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008-2024).

Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, Mohamed Salem, Ashley Meyer, Tiffany Chang, Madeline Ewing, Luiza Freire, Nathalie Murphy, Sabrina Renteria and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience applied, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Salma AbdelmotelebCedars-Sinai Health System, Los Angeles, CA, USA.
Jayant TotlaniVirginia Commonwealth University Health System, Richmond, VA, USA.
Salma RamadanCedars-Sinai Health System, Los Angeles, CA, USA.
Mohamed SalemCedars-Sinai Health System, Los Angeles, CA, USA.
Ashley MeyerUniversity of California Irvine, School of Medicine, Irvine, CA, USA.
Tiffany ChangCedars-Sinai Health System, Los Angeles, CA, USA.
Madeline EwingCedars-Sinai Health System, Los Angeles, CA, USA.
Luiza FreireFaculdade Pernambucana de Saude, Recife, PE, Brazil.
Nathalie MurphyCedars-Sinai Health System, Los Angeles, CA, USA.
Sabrina RenteriaCedars-Sinai Health System, Los Angeles, CA, USA.
Romana DymkoskiCedars-Sinai Health System, Los Angeles, CA, USA.
Omer LiranCedars-Sinai Health System, Los Angeles, CA, USA.
Rebecca HedrickCedars-Sinai Health System, Los Angeles, CA, USA.
Itai DanovitchCedars-Sinai Health System, Los Angeles, CA, USA.
Robert N PechnickWestern University of Health Sciences, Pomona, CA, USA.
Waguih William IsHakCedars-Sinai Health System, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This systematic review evaluates psychiatric medications for schizophrenia approved between 2008 and 2024, considering regulatory practices and approvals across multiple regions, including the United States, Europe, and Asian countries. It details the mechanism of action, indications, efficacy, dosing, and adverse effects of each medication. The methodology involved a literature search of the PubMed database for studies published from 2008 to December 31, 2024 on FDA-approved psychiatric medications and Phase 3 pipeline medications, along with additional medications approved in Europe using the keywords "schizophrenia" OR "psychosis" AND "psychopharm∗" OR "medic∗" OR "pharm∗." An independent assessment was conducted, followed by a consensus on eligible studies for inclusion in the systematic review. From 2008 to December 31, 2024, the FDA approved 29 medications for schizophrenia including 13 long-acting injectables (LAI), in addition to that there are additional three other medications that are available in Europe but not in the United States. Additionally, 8 pipeline medications are currently in Phase-3 clinical trials including one LAI. Each medication is analyzed, and its mechanisms of action, indications, dosing, efficacy, and adverse effects are described. The 13 approved LAIs and the one LAI in the pipeline are detailed in a separate manuscript. This review highlights a significant increase in approved medications for the treatment of schizophrenia, including long-acting injectable formulations that enhance the range of existing oral therapies. Furthermore, new treatments for medication-related movement disorders have been introduced. Innovative developments in Phase-3 trials for schizophrenia medications, including new mechanisms of action and administration routes, promise to transform treatment strategies and enhance patient outcomes.

Indexed as

Psychiatric disordersPsychiatric medicationsPsychosisSchizophrenia

Identifiers

PMID40654581
PMCPMC12244209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.